Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 8/20 | 0.52 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | ALB | P02768 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19662165 | 0.85 | TK1 (0.61) | TK1RNASE1LMNATSHRALB | |
| SCHEMBL21787087 | 0.84 | TK1 (0.46) | TK1RNASE1 | |
| SCHEMBL21786791 | 0.83 | POLB (0.61) | TK1 | |
| SCHEMBL21786906 | 0.82 | TK1 (0.52) | TK1RNASE1 | |
| SCHEMBL21786773 | 0.82 | TK1 (0.55) | TK1 | |
| SCHEMBL24730302 | 0.81 | TK1 (0.51) | TK1RNASE1LMNATSHRALB | |
| SCHEMBL8424863 | 0.80 | RNASE1 (0.53) | TK1RNASE1LMNAALBPKM | |
| SCHEMBL8424862 | 0.80 | RNASE1 (0.53) | TK1RNASE1LMNAALBPKM | |
| SCHEMBL23734388 | 0.79 | RNASE1 (0.61) | TK1RNASE1LMNATSHRALB | |
| SCHEMBL24913386 | 0.79 | TK1 (0.49) | TK1RNASE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200069717-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (US) | 2020-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200069717-A1 | NUCLEOTIDE DERIVATIVES AND METHODS OF USE THEREOF | POLRMT, NSUN2, RNGTT | TK1 254/4885RNASE1 212/4885LMNA 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.